1Unger T. Neuro hormonal modulation in cardiovascular disease [J] .Am Heart J, 2000, 139:2.
2Burns KD.Angiotensin and its receptors in the diabetic kidney [J] . Am J Kidney Dis, 2000, 36(3):449.
3Bouer JH, Ream GP. The Angiotensin Ⅱ type receptor antagonists. A new class of antihypertensive drugs[J ] .ArchInternMed, 1995, 155: 1361.
4de Boer RA, van Veldhuisen DJ, Gans RO, et al. Treatment of hypertension: angiotensin-Ⅱ antagonists potentially better than beta-blockers in the occurrence of cardiovascular and cerebrovascular damage; the LIFE study in perspective[ J] . Ned Tijdsehr Geneeskd, 2003, 147(3):96.
5Unger T, Rangoonwala B, Rosenthal J. ACE inhibitor or AT1 antagonist, Is there a differential therapy[J] .MMW Fortschr Med, 2002, 144(24):36.
6Pitt B, Segal R, Martinez FA, et al. Randomised trial of Losartan versus Captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)[J] .Lancet, 1997, 349: 747.
7Pierard L. Clinical study of the month. Effects of valsartan in chronic heart failure: the VAL-HeFT study[J] .Rev Med Liege, 2002, 57(1):57.
8Wong M, Staszewsky L, Latini R, et al. Valsartan benefits left ventricular structure and function in heart failure:Val-HeFT echocardiographic study[ J] . J Am Coll Cardiol, 2002, 40(5): 970.
9Maggioni AP, Ammd I, Gottlieb SO, et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors [J] . J Am Coll Cardiol, 2002, 40(8): 1414.
10Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme [J] . Lancet, 2003, 362(9386):759.
